Anaplastic thyroid carcinoma (ATC) · line 1 · Dabrafenib + trametinib (anaplastic thyroid carcinoma, BRAF V600E)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-DAB-TRAM-ATC |
| ID | IND-ATC-BRAF-V600E-DAB-TRAM |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-04 | pending_clinical_signoff |
| Diseases | DIS-THYROID-ANAPLASTIC |
| Sources | SRC-NCCN-THYROID-2025 SRC-ROAR-SUBBIAH-2018 |
Notes
ATC BRAF V600E targeted therapy — fills the gap in ALGO-THYROID-ANAPLASTIC-1L which previously only routed to palliative paclitaxel-carboplatin. ROAR PMID 29360941 is now ingested as SRC-ROAR-SUBBIAH-2018. Updated 2022 ROAR cohort (PMID 34731050, JCO 2022) shows n=36, ORR 56%, mDOR 8.7 mo — slightly lower ORR than original report but durable responses.
Used By
Algorithms
ALGO-THYROID-ANAPLASTIC-1L- ALGO-THYROID-ANAPLASTIC-1L